Summary
Recent preclinical studies have suggested that radiotherapy in combination with antiangiogenic/vasculature-targeting agents enhances the therapeutic ratio of ionizing radiation. Because radiotherapy is one of the most widely used treatments for cancer, it is important to understand how best to use these two modalities to aid in the design of rational patient protocols. The mechanisms of interaction between antiangiogenic/vasculature-targeting agents and ionizing radiation are complex and involve interactions between the tumor stroma and vasculature and the tumor cells themselves. These agents can decrease overall tumor resistance to radiation by affecting both tumor cells and tumor vasculature, thereby breaking the codependent cycle of tumor growth and angiogenesis. Because the mechanisms of interaction between ionizing radiation and antiangiogenic/vascular targeting agents are not fully understood, the ideal way to use this potentially powerful combination for tumor cure has yet to be determined. We have described a number of possible mechanisms of interaction between antiangiogenic agents and radiation.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ferrara, N., Gerber, H. P., & LeCouter, J. 2003. The biology of VEGF and its receptors. Nat Med 9: 669–676.
Nieder, C., Wiedenmann, N., Andratschke, N., & Molls, M. 2006. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev 32: 348–364.
McMahon, G. 2000. VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1): 3–10.
Dvorak, H. F. 2002. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368–4380.
Tozer, G. M. & Bicknell, R. 2004. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 14: 222–232.
Wachsberger, P., Burd, R., & Dicker, A. P. 2004. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 18: 1039–1057, viii.
Semenza, G. L. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551–578.
Jain, R. K. 2003. Molecular regulation of vessel maturation. Nat Med 9: 685–693.
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., et al. 1999. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374–3378.
Lanza-Jacoby, S., Dicker, A. P., Miller, S., Rosato, F. E., Flynn, J. T., Lavorgna, S. N., et al. 2004. Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther 3: 417–424.
Saha, D., Pyo, H., & Choy, H. 2003. COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am J Clin Oncol 26: S70–S74.
Steinauer, K. K., Gibbs, I., Ning, S., French, J. N., Armstrong, J., & Knox, S. J. 2000. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 48: 325–328.
Dent, P., Yacoub, A., Contessa, J., Caron, R., Amorino, G., Valerie, K., et al. 2003. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159: 283–300.
Wachsberger, P. R., Burd, R., Marero, N., Daskalakis, C., Ryan, A., McCue, P., et al. 2005. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11: 835–842.
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A., Horsman, M. R., et al. 2005. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 11: 416–420.
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S. S., Booth, M. F., Garkavtsev, I., et al. 2004. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553–563.
Lee, C. G., Heijn, M., di, T. E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., et al. 2000. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565–5570.
Jain, R. K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62.
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., et al. 2004. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165: 35–52.
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. 2004. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64: 3731–3736.
Ansiaux, R., Baudelet, C., Jordan, B. F., Beghein, N., Sonveaux, P., De, W. J., et al. 2005. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11: 743–750.
Ansiaux, R., Baudelet, C., Jordan, B. F., Crokart, N., Martinive, P., Dewever, J. et al. 2006. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 66: 9698–9704.
McCarty, M. F., Wey, J., Stoeltzing, O., Liu, W., Fan, F., Bucana, C., et al. 2004. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3: 1041–1048.
Thaker, P. H., Yazici, S., Nilsson, M. B., Yokoi, K., Tsan, R. Z., He, J., et al. 2005. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res 11: 4923–4933.
Dings, R. P., Williams, B. W., Song, C. W., Griffioen, A. W., Mayo, K. H., & Griffin, R. J. 2005. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 115: 312–319.
Willet C., Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 8136–8138 [correspondence], 2006.
Seiwert T. Y., Haraf D. J., & Cohen E. E. 2006. A phase I study of bevacizumab with fluorouracil and hydroxyurea with oncomitant radiotherapy for poor prognosis head and neck cancer. Proc Am Soc Clin Oncol A5530: 287s.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press
About this chapter
Cite this chapter
Mendoza, E., Burd, R., Wachsberger, P., Dicker, A.P. (2008). Normalization of Tumor Vasculature and Improvement of Radiation Response by Antiangiogenic Agents. In: Teicher, B.A., Ellis, L.M. (eds) Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-184-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-59745-184-0_18
Publisher Name: Humana Press
Print ISBN: 978-1-58829-870-6
Online ISBN: 978-1-59745-184-0
eBook Packages: MedicineMedicine (R0)